Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 5 July 2006. doi:10.1136/jcp.2006.040170
Journal of Clinical Pathology 2007;60:500-503
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

ORIGINAL ARTICLE

Validation of tissue microarray technology in endometrioid cancer of the endometrium

Guus Fons1, Siti M Hasibuan2, Jacobus van der Velden1 and Fiebo J W ten Kate3

1 Academic Medical Centre, Department of Obstetrics and Gynaecology, Amsterdam, The Netherlands
2 Dr Pirngadi Hospital, Department of Anatomical Pathology, Medan, Indonesia
3 Academic Medical Centre, Department of Pathology, Amsterdam, The Netherlands

Correspondence to:
Correspondence to:
Dr G Fons
Academic Medical Centre Department of Obstetrics and Gynaecology Meibergdreef 9 1100 DD Amsterdam The Netherlands;g.fons{at}amc.uva.nl

Aim: To validate tissue microarray (TMA) for endometrial cancer by comparing immunohistochemical staining results of triplicate core biopsies on TMA with the results of full-section analysis.

Methods: The study material consisted of slides and selected tissue blocks of 41 patients with endometrioid cancer of the endometrium. A TMA was constructed. Both the TMA and the slides were stained with the same antibodies against progesterone receptor (PR), oestrogen receptor, p53 and epithelial membrane antigen (EMA). Concordance between results was expressed as the {kappa} statistic.

Results: Concordance between the staining results of TMA and whole slides was good for PR ({kappa} = 0.69), oestrogen receptor ({kappa} = 0.78), p53 ({kappa} = 0.81) and EMA ({kappa} = 0.72). Concordance between the results on TMA and slides depends on the number of assessable cores per tumour. Three assessable cores per case result in outcomes that are at least 94% similar to those achieved using conventional tissue sections with a two-class scoring system. This is independent of focal or diffuse staining patterns.

Conclusion: TMA is a useful tool for further analysis of the molecular pathways in endometrial cancer. The effect of selection has to be taken into account when the prognostic value of protein expression on TMA is determined.

Abbreviations: EMA, epithelial membrane antigen; PR, progesterone receptor; TMA, tissue microarray


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Cunha, K S. G., Caruso, A C., Goncalves, A S., Bernardo, V G., Pires, A R. C., da Fonseca, E C., de Faria, P A. S., da Silva, L E., Geller, M, de Moura-Neto, R S., Lopes, V S. (2009). Validation of tissue microarray technology in malignant peripheral nerve sheath tumours. J. Clin. Pathol. 62: 629-633 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs